Literature DB >> 2757528

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.

R J Barohn1, J T Kissel, J R Warmolts, J R Mendell.   

Abstract

Over a 10-year period, we followed up 60 patients (35 men and 25 women) with chronic inflammatory demyelinating polyradiculoneuropathy. Diagnosis was based on previously outlined criteria. Patients were treated in a uniform manner and the overwhelming majority, 56 (94.9%) of 59 treated patients, initially responded to immunosuppressive therapy. The time for initial improvement was 1.9 +/- 3.6 months while the time to reach a clinical plateau was 6.6 +/- 5.4 months. The course was monophasic in 32 patients (53.3%) and relapsing in 28 (46.6%). Despite the initial responsiveness, only 24 (40%) of 60 patients are in partial or complete remission, receiving no medication. Two patients died. We were unable to identify specific clinical or laboratory features at the time of diagnosis that predicted outcome. Our data analysis, along with previous reports, suggests that chronic inflammatory demyelinating polyradiculoneuropathy may be more heterogeneous than previously emphasized. In this light, we have proposed diagnostic criteria that allow for the heterogeneity but at the same time provide for a more consistent approach to better establish the natural history of this condition.

Entities:  

Mesh:

Year:  1989        PMID: 2757528     DOI: 10.1001/archneur.1989.00520440064022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  74 in total

1.  Hepatocellular carcinoma presenting with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  M R Arguedas; B M McGuire
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

Review 2.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

3.  Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy.

Authors:  M Nagamatsu; S Terao; K Misu; M Li; N Hattori; M Ichimura; M Sakai; H Yamamoto; H Watanabe; S Riku; E Ikeda; J Hata; M Oda; M Satake; N Nakamura; S Matsuya; Y Hashizume; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 4.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

5.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 6.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

Review 7.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.

Authors:  Giovanni Pavesi; Luigi Cattaneo; Adriana Marbini; Franco Gemignani; Domenico Mancia
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

9.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments.

Authors:  R Nemni; S Amadio; R Fazio; G Galardi; S Previtali; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 10.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.